Janssen-Cilag Ltd.
Clinical Trials
33
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
A Real-world Study in Participants With Smoldering Multiple Myeloma
- Conditions
- Smoldering Multiple Myeloma
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06472778
- Locations
- 🇫🇷
CHRU de Tours - Hopital Trousseau, Chambray Les Tours, France
🇫🇷CHU Montpellier, Montpellier, France
🇫🇷Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source, Orleans, France
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06408935
- Locations
- 🇩🇪
Medizinisches Versorgungszentrum (MVZ) Dachau, Dachau, Germany
🇮🇹Fondazione Policlinico Tor Vergata, Roma, Italy
🇮🇹IRCCS Humanitas Rozzano-IBD Center Malattie Infiammatorie Croniche Intestinali, Rozzano, Italy
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06285318
- Locations
- 🇩🇰
Aalborg Sygehus Syd, Aalborg, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 516
- Registration Number
- NCT05901649
- Locations
- 🇦🇹
Klinikum Wels Grieskirchen, Wels, Austria
🇦🇹Akh Wien, Wien, Austria
🇫🇷Institut Sainte Catherine, Avignon, France
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
- Conditions
- Fistulizing Crohns DiseasePerianal Crohns Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05347095
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Miami, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next